Nom du produit:[(2R)-1-(1H-indazol-4-yl)propan-2-yl](2,2,2-trifluoroethyl)amine
IUPAC Name:[(2R)-1-(1H-indazol-4-yl)propan-2-yl](2,2,2-trifluoroethyl)amine
- CAS：2142634-00-0
- Formule moléculaire：C12H14F3N3
- Pureté：95%+
- Numéro de catalogue：CM1075326
- Poids moléculaire：257.26
| Unité d'emballage |
Stock disponible |
Prix($) |
Quantité |
Pour une utilisation en R&D uniquement..
Détails du produit
- N° CAS:2142634-00-0
- Formule moléculaire:C12H14F3N3
- Point de fusion:-
- Code SMILES:C[C@H](CC1=C2C=NNC2=CC=C1)NCC(F)(F)F
- Densité:
- Numéro de catalogue:CM1075326
- Poids moléculaire:257.26
- Point d'ébullition:
- N° Mdl:
- Stockage:
Category Infos
- Indazoles
- Indazoles are a class of organic heterocyclic compounds, also known as 1,2-diazaindene and benzopyrazole. Indazole is a good bioisomer of phenol, which is more lipophilic than phenol and less prone to phase I and II metabolism. Indazole derivatives have a wide range of biological activities, and it has been confirmed that indazole compounds have anti-tumor, analgesic, anti-inflammatory and other drug activities. Anticancer is the most important application field of indazole drugs. Renal cell carcinoma, solid tumor, nausea and vomiting caused by chemotherapy and leukemia are the main indications of this structural backbone drug.
Column Infos
- Camizestrant
- Recently, Evaluate Pharma released an analysis report on the trends in the biopharmaceutical industry in 2024. The report mentioned 10 potential key R&D pipelines, including the small molecule drug camizestrant. Camizestrant is a next-generation oral SERD and pure Erα antagonist that has demonstrated anti-cancer activity across a range of preclinical models, including in patients with ER-activating mutations.
Recherche 
+86 21 5895 0110 
